Marco Timmers

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 208 citations

Breast Oncology, Immunology, Pathology +20

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H.A. Dokter, Ruud Ubink, Miranda van der Lee et al. · Molecular Cancer Therapeutics · 2014 · 156 citations · Full text

Drug Target, Immunology, Molecular Biology +18

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

Gerard Rouwendal, Miranda MC van der Lee, Saskia Meyer et al. · mAbs · 2015 · 48 citations · Full text

Anti-her2 Iga, Vivo Half-life, Glycobiology +16

Complete Inhibition of rhTSH-, Graves' Disease IgG-, and M22-Induced cAMP Production in Differentiated Orbital Fibroblasts by a Low-Molecular-Weight TSHR Antagonist

Clementine J.J. van Zeijl, Chris J. van Koppen, Olga V. Surovtseva et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 39 citations · Full text

Immunology, Immunologic Mechanism, Pharmacotherapy +19

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Mary J. van Helden, Seline A. Zwarthoff, Roel J. Arends et al. · Journal for ImmunoTherapy of Cancer · 2023 · 13 citations · Full text

Immunology, Immunoediting, Cell Death +18